

Dear Healthcare Partner,

This issue features updated patient resources to support patient involvement and informed decision-making, alongside new and updated health technology guidance across a range of clinical areas.

AT A GLANCE THIS MONTH

- Patient resources to support better understanding of technical terms and share opportunities for patient involvement in ACE's work
- Guidance documents on diagnostic and therapeutic technologies

Highlights



This month's highlight includes an updated resource to support patient conversations.

- Updated **Patient Glossary** provides simple definitions to help patients and carers better understand technical terms commonly used in ACE's work.

Patient Resources

To support patient conversations:

- Updated [Patient Glossary](#)
- Updated factsheet on "[How to suggest health technologies for ACE to evaluate?](#)"
- Updated learning module on "[How do patients contribute to ACE's work?](#)"

💡 Supports discussion on treatment options and shared decision-making

Health Technology Guidance

Latest assessments of health technologies to support clinical, funding, and planning decisions:

NEW

Drug Guidance

Bladder Cancer:

- [Enfortumab vedotin in combination with pembrolizumab for untreated locally advanced or metastatic urothelial cancer](#)

Breast Cancer:

- [Elacestrant for ER-positive, HER2-negative, locally advanced or metastatic breast cancer with an activating ESR1 mutation](#)

Lung Cancer:

- [Durvalumab for limited-stage small-cell lung cancer](#)
- [Selpercatinib for locally advanced or metastatic RET-fusion positive non-small-cell lung cancer](#)

Lymphoma:

- [Acalabrutinib in combination with bendamustine and rituximab for previously untreated mantle cell lymphoma](#)
- [Glofitamab for relapsed or refractory diffuse large B-cell lymphoma not otherwise specified in patients who are not candidates for autologous stem cell transplant](#)

Pancreatic Cancer:

- [Liposomal irinotecan for first-line treatment of metastatic adenocarcinoma of the pancreas](#)

Thyroid Cancer:

- [Selpercatinib for advanced or metastatic thyroid cancer with RET alterations](#)

Neuroendocrine Cancer:

- [Cabozantinib for previously treated well-differentiated pancreatic or extra-pancreatic neuroendocrine tumours](#)

Upper Gastrointestinal Cancer:

- [Tislelizumab for untreated HER2-negative, unresectable advanced gastric or gastroesophageal junction adenocarcinoma](#)

Multi-Indication Cancer Drugs:

- [Belzutifan for von Hippel-Lindau disease with associated non-metastatic renal cell carcinoma, central nervous system hemangioblastomas, or pancreatic neuroendocrine tumours](#)

Respiratory Condition:

- [Biologics as add-on therapy for treating chronic rhinosinusitis with nasal polyps](#)
- [Nirsevimab for prevention of respiratory syncytial virus-associated lower respiratory tract disease in infants during their first RSV season](#)

Cardiovascular Condition:

- [Vutrisiran for transthyretin amyloid cardiomyopathy](#)

Infectious Disease:

- [Maribavir for treating refractory or drug-intolerant cytomegalovirus infection after transplant](#)

Medical Technology Guidance

Cardiovascular Condition:

- [Intracardiac monitor for Acute Coronary Syndrome event detection](#)

UPDATED

Drug Guidance

Upper Gastrointestinal Cancer:

- [Zolbetuximab for untreated HER2-negative, claudin-18.2-positive, unresectable advanced gastric or gastroesophageal junction adenocarcinoma](#)

Neurological Condition:

- [Disease-modifying therapies for treating multiple sclerosis](#)
- [Nusinersen and risdiplam for treating spinal muscular atrophy](#)
- [Eplontersen and vutrisiran for hereditary transthyretin amyloidosis with polyneuropathy](#)

Medical Technology Guidance

Diabetes Management:

- [Continuous subcutaneous insulin infusion therapy for treating type 1 diabetes](#)

Explore more guidance, guidelines and resources on our ACE website: www.ace-hta.gov.sg

Follow us for the latest updates:

